Please provide your email address to receive an email when new articles are posted on . The goal of a new EULAR initiative linking trial centers across Europe is quicker, more efficient clinical ...
Please provide your email address to receive an email when new articles are posted on . A new trial center network and two major data collection projects are among recent EULAR initiatives for ...
Create a network of clinical trial centres, accessible to all investigators and sponsors from both public and private sectors. Build capacity and training in clinical trials and experimental medicine ...
-- Patients with moderate-to-severe systemic disease activity (ESSDAI score ≥5) treated with dazodalibep experienced improvement in their disease activity (6.3-point reduction) compared to those who ...
STOCKHOLM, May 28, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) will present new clinical data and research outcomes at the annual European Congress of Rheumatology (EULAR 2025) in Barcelona from the 11-14 ...
COPENHAGEN -- A randomized trial reported here appears to confirm that, contrary to guidance from major rheumatology societies, years-long use of corticosteroids in older rheumatoid arthritis (RA) ...
SANDWICH, United Kingdom, June 12, 2025 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for osteoarthritis, is to present ...
NEW YORK and MELBOURNE, Australia, June 22, 2017 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) announced that results from the randomized, placebo-controlled 48-patient Phase 2 trial ...
-- Patients with moderate-to-severe systemic disease activity (ESSDAI score ≥5) treated with dazodalibep experienced improvement in their disease activity (6.3-point reduction) compared to those who ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback